Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Transthyretin (TTR) is associated with several human amyloid diseases. Various kinetic stabilizers have been developed to inhibit the dissociation of TTR tetramer and the formation of amyloid fibrils. Most of them are bisaryl derivatives, natural flavonoids, crown ethers and carborans. In this review article, we focus on TTR tetramer stabilizers, genetic therapeutic approaches and fibril remodelers. The binding modes of typical bisaryl derivatives, natural flavonoids, crown ethers and carborans are discussed. Based on knowledge of the binding of thyroxine to TTR tetramer, many stabilizers have been screened to dock into the thyroxine binding sites, leading to TTR tetramer stabilization. Particularly, those stabilizers with unique binding profiles have shown great potential in developing the therapeutic management of TTR amyloidogenesis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4155/fmc-2021-0248 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of L110M Mutation on the Structure and Stability of ATTR(105-115) Peptide Assembly: A Computational Study.
Proteins
September 2025
School of Advanced Sciences and Languages (SASL), VIT Bhopal University, Sehore, Madhya Pradesh, India.
The mechanisms driving amyloid assembly have long intrigued structural biologists, as they offer insights into systemic fibrotic changes and the dynamic behavior of transthyretin (TTR) aggregation, crucial for developing amyloid-targeted therapies. In TTR-associated amyloidosis, amyloid fibrils form via destabilization of the tetramer into dimers and monomers. While many TTR mutations have been studied, the atomistic impact of multiple mutations on amyloid transthyretin (ATTR) self-assembly remains underexplored.
View Article and Find Full Text PDFEffect of G83R Mutation on Transthyretin Protein Structural Stability.
ACS Omega
August 2025
Department of Ophthalmology, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China.
Transthyretin (TTR) G83R mutation can cause vitreous amyloidosis and severely impair vision. Further understanding of the effect of G83R mutation on the TTR structure and stability will help to understand its pathogenesis. This study investigated the thermodynamic and dynamic stabilities, as well as fibril formation, of TTR G83R and compared them with those of wild-type TTR and V30 M variants.
View Article and Find Full Text PDFHereditary Transthyretin Amyloidosis: Genetic Characterization of the P.Val142Ile Variant in a Calabrian Kindred.
Genes (Basel)
August 2025
Medical Genetics Unit, Renato Dulbecco University Hospital, 88100 Catanzaro, Italy.
Background: Hereditary transthyretin amyloidosis (ATTRv) is a systemic disorder caused by homozygosity or compound heterozygosity for pathogenic mutations in the gene, leading to destabilization of the transthyretin tetramer, misfolding of monomers, and subsequent amyloid fibril deposition. Among over 150 known variants, p.Val142Ile is particularly associated with late-onset cardiac involvement and is the most prevalent amyloidogenic mutation in individuals of African and, to a lesser extent, European descent.
View Article and Find Full Text PDFMechanism of inhibition of acid-mediated transthyretin aggregation by designed peptides.
J Biol Chem
August 2025
Department of Integrative Structural and Computational Biology and Skaggs Institute of Chemical Biology, The Scripps Research Institute, La Jolla, CA, U.S. Electronic address:
Aggregation of transthyretin (TTR) causes TTR cardiomyopathy and polyneuropathy through amyloidosis. To initialize TTR aggregation, the native TTR tetramer first dissociates to a monomeric intermediate, which misfolds and self-assembles to oligomers, eventually forming insoluble aggregates and fibrils. Peptide inhibitors have been designed to cap two β-strands that are buried in the well-folded tetramer but are solvent-exposed in the monomeric aggregation intermediate.
View Article and Find Full Text PDFHuman transthyretin (TTR) is a homotetrameric protein involved in transporting thyroxine (T4) and retinol-binding protein within serum and cerebrospinal fluid. The disassociation of TTR's tetrameric structure can lead to the formation of biologically toxic TTR amyloid fibrils. Tolcapone, a small molecule currently under clinical trial, has shown potential as a TTR stabilizer and may act as an alternative to tafamidis, the conventional therapeutic agent used to prevent TTR dissociation.
View Article and Find Full Text PDF